China’s Vaccine Congress Draws Pharmaceutical MNCs
This article was originally published in PharmAsia News
Executive SummaryMore than 300 scientists and executives from pharmaceutical MNCs congregated at the recent First World Vaccine Congress held in Guangdong, China. Participants included top officials from the International Vaccine Institute of Korea, Baxter International, Intercell and GSK, reflecting overseas companies' optimism in the country's vaccine market. The event aimed to boost the internationalization of China's vaccine industry, speeding up changes in its production and biotechnology. Although major vaccine player Baxter has not started its vaccine business in China, it has been keeping a close eye on the country and analysts believe it will enter the market soon. Baxter considers China a high-priority international market, especially for vaccine products. (Click here for more - Chinese Language)
You may also be interested in...
ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.
Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac
Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.
In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.